{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:02:14Z","timestamp":1790337734683,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021564","name":"Unicancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dld.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T19:42:11Z","timestamp":1788118931000},"page":"1252-1258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 \u2013 GRACIE trial"],"prefix":"10.1016","volume":"58","author":[{"given":"Judith","family":"Raimbourg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Botsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9lia","family":"Coutzac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"De Sousa Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-6196","authenticated-orcid":false,"given":"Cristina","family":"Smolenschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-5693","authenticated-orcid":false,"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.08.003_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.dld.2026.08.003_bib0002","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.dld.2026.08.003_bib0003","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjsurg.2005.10.015","article-title":"Selection of patients with gastric adenocarcinoma for laparoscopic staging","volume":"191","author":"Sarela","year":"2006","journal-title":"Am J Surg"},{"key":"10.1016\/j.dld.2026.08.003_bib0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jama.2025.20034","article-title":"Gastric cancer: a review","volume":"335","author":"Patel","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2026.08.003_bib0005","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fmed.2022.1002435","article-title":"The evolving strategies for the management of patients with metastatic gastric cancer: a narrative review and expert opinion","volume":"9","author":"Cascinu","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.dld.2026.08.003_bib0006","doi-asserted-by":"crossref","first-page":"21905","DOI":"10.1002\/cam4.6765","article-title":"The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression","volume":"12","author":"Jing","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.dld.2026.08.003_bib0007","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-18-1128","article-title":"Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma","volume":"24","author":"Kato","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2026.08.003_bib0008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.dld.2026.08.003_bib0009","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.08.003_bib0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.08.003_bib0011","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.08.003_bib0012","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.08.003_bib0013","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2026.08.003_bib0014","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.08.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102890","article-title":"How do I treat dMMR\/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force","volume":"134","author":"de la Fouchardi\u00e8re","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.dld.2026.08.003_bib0016","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.08.003_bib0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.08.003_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010043","article-title":"Angiogenesis and anti-angiogenic therapy in gastric cancer","volume":"19","author":"Nienh\u00fcser","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dld.2026.08.003_bib0019","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.dld.2026.08.003_bib0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.dld.2026.08.003_bib0021","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.08.003_bib0022","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.08.003_bib0023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.08.003_bib0024","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","article-title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","volume":"406","author":"Chen","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.08.003_bib0025","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2025.09.017","article-title":"PL02.12 ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi","volume":"20","author":"Goldman","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.dld.2026.08.003_bib0026","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.08.003_bib0027","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO-25-00748","article-title":"Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced metastatic gastroesophageal adenocarcinoma: the phase III, randomized LEAP-015 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.08.003_bib0028","doi-asserted-by":"crossref","first-page":"S1622","DOI":"10.1016\/j.annonc.2025.09.095","article-title":"LBA80 Regorafenib plus nivolumab vs investigator's choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG intergroup [NHMRC-CTC\/IKF\/AIO, ACCRU, TCOG\/NHRI] study","volume":"36","author":"Goldstein","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.08.003_bib0029","article-title":"Cadonilimab in combination with ivonescimab and chemotherapy as first-line (1L) therapy in patients with advanced gastric (G) or gastroesophageal junction adenocarcinoma (GEJA)","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826008881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826008881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:19:28Z","timestamp":1790335168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826008881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1590865826008881"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.08.003","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 \u2013 GRACIE trial","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}